Watch On Demand Available Now
Optimer ligands to hit new targets and challenging tissues
Developing new assays, engaging new targets and accurately detecting specific biomarkers is difficult without fit-for-purpose ligands. While antibodies have long been the accepted gold standard, a number of drawbacks are inherent in their development and production that limit their use in some circumstances. Optimer ligands are aptamers optimized to overcome many of these issues for a wider target range, rapid development, improved manufacturability and batch consistency. Watch this webinar to understand how this technology is being applied to new assays and targets.
In this webinar, you will learn about
- Learn how Optimer ligands can be customized specifically for the required target, assay and application through our flexible platform and toolkit for the best performance and integration
- Find out how Optimer binders cut 70% of the timelines compared to traditional antibody reagents
- Learn how Optimer ligands can be developed in a biomarker-free way to open up new targets for challenging diseases
- Learn about Optimer applications for new diagnostics, affinity purification and targeted delivery of small molecule and gene therapy payloads
Dr David Bunka
Chief Technical Officer
"David holds a Ph.D. in Molecular Biology and has spent nearly 20 years developing nucleic acid aptamers against a wide variety of targets including small molecules (antibiotics, food contaminants, chemotherapeutics), disease-associated proteins, several cancer-associated cell-lines, viruses and tissue biopsies. This work has been facilitated through the use of high-throughput, automated aptamer selection methods. David has built up an established international reputation in the field and has authored several peer-reviewed research articles, invited review articles and a book chapter on aptamer-based therapeutics. He has also given many guest seminars covering aptamer-based applications at top universities and international conferences."